Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-5,page-paged-5,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.3.0,vc_responsive

CLIENT NEWS

 

 

  • Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners
    www.relieftherapeutics.com
  • Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020
    www.adocia.com
  • InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
    www.inflarx.de
  • Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease
    www.veronapharma.com
  • Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes
    www.adocia.com
  • Relief Reports Half-Year 2020 Results
    www.relieftherapeutics.com
  • Newron announces half-year 2020 results
    www.newron.com
  • Adrenomed AG: Data from Adrenomed’s AdrenOSS-2 trial with Adrecizumab in Septic Shock to be presented during e-ISICEM
    www.andrenomed.com
  • 4basebio AG comments on the takeover bid of Sparta AG
    www.4basebio.com
  • InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia
    www.inflarx.de